

PHARMING RECEIVES COMMITMENT FOR CONVERSION OF 70% OF OUTSTANDING BONDS Extension of offer period for logistical reasons

Leiden, The Netherlands, September 30, 2009. Biotech company Pharming Group NV ("Pharming" or the "Company") (NYSE Euronext: PHARM) has received commitment from bondholders, representing 70% of the nominal amount of the currently outstanding bonds, to accept the offer to convert the bonds as announced on September 21, 2009. Together, they exceed the threshold level of 60% which Pharming set as a minimum participation in order to execute the transaction.

At the request of certain bondholders and for the purpose of completing the logistics of the applications for conversion, the offer period has been extended by two weeks until October 13, 2009. Bondholders, who have not yet returned a conversion application and wish to participate in the offer, may still do so by completing the application. Further details are described in the formal announcement on the Company's website.

On September 21, 2009, Pharming made a public offer to the holders of convertible bonds (issued in 2007) to convert their bonds into a combination of cash and shares. Under the proposed transaction, Pharming offers € 7,500 cash and 59,000 shares for each outstanding bond with a nominal value of € 50,000. Following conversion of 70% of the bonds, the total amount of outstanding debt from the convertible bonds will be reduced from € 35.8 million to € 10.9 million. This transaction will amount to 29.38 million newly issued shares and € 3.74 million cash to be paid.

Dr. Sijmen de Vries, Chief Executive Officer, commented: "We are very pleased that 70% of our outstanding convertible debt will be removed from our balance sheet following the completion of this transaction. While the logistics involved with completing the transaction are completed over the next days, we will continue to accept any further applications for conversion. This transaction significantly strengthens our balance sheet and will open the way for additional deals that should further improve our financial position."

This is not an offering memorandum or a prospectus and should not be treated as offering material of any sort and is for information purposes only. Not for distribution to any US person or in or into the United States or to any Italian person or address in the republic of Italy.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human Lactoferrin for use in food products and one product in early stage clinical development - Prodarsan® for Cockayne Syndrome. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, <http://www.pharming.com>.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact:

Ms. Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54